<DOC>
	<DOC>NCT01689571</DOC>
	<brief_summary>The study is designed to look at the safety, tolerability and efficacy of 2 different doses of the study drug (CHF6001, a PDE4 inhibitor) in asthmatics, when given by inhalation, once a day for 9 days. The efficacy will be evaluated by measuring the protective effect of CHF 6001 after an allergen challenge.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>written informed consent obtained Non smoking or exsmokers from at least 1 year prior to study entry Males of females between 18 and 60 years inclusive Body Mass Index between 18 and 32 kg/m2 Ability to be trained about the proper use of the inhalation device and to perform spirometry With mild to moderate allergic asthma as defined by the GINA guideline, steroid naive Atopy to at least one common aeroallergen Positive allergeninduced Early Asthmatic Response and Late Asthmatic Response at screening Ability to produce an adequate sputum sample Postmenopausal women, women of not childbearing potential or males and females of childbearing potential willing (they or their partner) to use a reliable method of contraception. Worsening of asthma or respiratory tract infection prior to study entry History of lifethreatening asthma or hospitalization for asthma prior to the study entry Pregnant or lactating women History of clinically significant hypotensive episodes or fainting, dizziness or lightheadedness History or symptoms of clinically relevant neurologic disease Symptomatic hay fever Unstable concurrent disease that may impact the feasibility of the study Use of systemic corticosteroids, nebulised bronchodilator or oral beta2agonist Use of leukotrienes modifiers, roflumilast or cromoglycate Use of long acting beta2agonist or inhaled corticosteroids Use of shortacting or longacting nonsedatives antihistamines Use of any other medication for the treatment of allergic asthma other than salbutamol Having received an investigational medicinal drug within 30 days prior to study entry Blood drawn of at least 250 ml in the previous 45 days Ongoing use of tobacco Other lung disease Recent history of alcohol dependency Inability to comply with the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDE4 inhibitor</keyword>
	<keyword>Allergen Challenge</keyword>
	<keyword>Asthma</keyword>
</DOC>